All lobbying filings
THE UNITED STATES PHARMACOPEIAL CONVENTION
THE UNITED STATES PHARMACOPEIAL CONVENTION filed a Q4 report for THE UNITED STATES PHARMACOPEIAL CONVENTION on January 20, 2026.
Lobbying for THE UNITED STATES PHARMACOPEIAL CONVENTION
Filing · LD-2 quarterly report
Q4 report
Reporting period
4th Quarter 2025
Oct 1 - Dec 31 · Posted Jan 20, 2026
Expenses
$100,000
What this organization spent lobbying with its own staff.
Reported using IRS section 6033(b)(8) definitions (method B): the three
LDA methods count different costs, so an expenses figure is
not comparable across filers that used different ones.
Client based in
Maryland
Government bodies contacted
2
Lobbying activity
3
H.R. 5304, S.2587 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026; H.R. 4779 National Security, Department of State, and Related Programs Appropriations Act, 2026: Provisions related to pharmaceutical supply chain resilience.
S. 2296 - National Defense Authorization Act for Fiscal Year 2026: Provisions regarding medicine supply chain.
S. 1784 - Mapping America's Pharmaceutical Supply (MAPS) Act; H.R. 4191: Provisions regarding supply chain security and resilience and drug shortages.